-transparent.png){kind=logo}
The efficacy and safety of 15 mg midazolam versus 15 mg oxazepam were compared in a double-blind clinical trial in 61 aged hospitalized patients (mean age 82.5, range 69 to 96), suffering from moderate to severe insomnia. The study covered 8 nights, i.e., 1 placebo night followed by 5 treatment nights and 2 further placebo nights. Both drugs were equally effective with respect to total sleep time, number of nocturnal awakenings, quality of sleep, condition on awakening, patients' assessment and dreams. However, sleep latency was significantly shorter in the midazolam group, which was also rated significantly more favorably by the medical staff. Side effects were mild and similar in both groups. No rebound or carry-over effects were noted. Midazolam can be considered an effective and safe sleep inducer in aged patients.
F Loew, and
C Pawlak, and
L Benaroyo, and
J P Junod
October 1983,
Acta anaesthesiologica Scandinavica,
F Loew, and
C Pawlak, and
L Benaroyo, and
J P Junod
December 1996,
Alimentary pharmacology & therapeutics,
F Loew, and
C Pawlak, and
L Benaroyo, and
J P Junod
December 1966,
The Journal of the Association of Physicians of India,
F Loew, and
C Pawlak, and
L Benaroyo, and
J P Junod
January 1983,
British journal of clinical pharmacology,
F Loew, and
C Pawlak, and
L Benaroyo, and
J P Junod
January 1986,
Acta psychiatrica Scandinavica. Supplementum,
F Loew, and
C Pawlak, and
L Benaroyo, and
J P Junod
September 1990,
The Journal of clinical psychiatry,
F Loew, and
C Pawlak, and
L Benaroyo, and
J P Junod
January 2023,
Brazilian journal of anesthesiology (Elsevier),
F Loew, and
C Pawlak, and
L Benaroyo, and
J P Junod
January 1983,
British journal of clinical pharmacology,
F Loew, and
C Pawlak, and
L Benaroyo, and
J P Junod
December 1973,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
F Loew, and
C Pawlak, and
L Benaroyo, and
J P Junod
January 2004,
Advances in therapy,
